PML is a rare but serious infection of the central nervous system (CNS). The Progressive Multifocal Leukoencephalopathy (PML) Consortium is a joint effort between Biogen Idec, Bristol-Myers Squibb, Pfizer, MedImmune and Roche intended to enhance the understanding of and identify more effective methods of predicting, preventing and treating PML.
Phase I Grant Proposal Deadline Passed
The deadline for Phase I proposals was February 14th. A new call for grants will be made in Fall 2014. More information
PML Conference ebriefing Posted
A written summary and recordings of select presentations from this year's PML Conference can be viewed at: www.nyas.org/PML2013-eB.